Iovance Biotherapeutics, Inc. (FRA:2LB)

Market Cap	836.12M
Revenue (ttm)	213.44M
Net Income (ttm)	-338.90M
Shares Out	n/a
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	838
Open	2.225
Previous Close	2.325
Day's Range	2.225 - 2.231
52-Week Range	1.431 - 6.958
Beta	n/a
RSI	55.35
Earnings Date	Feb 26, 2026

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 838
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2LB

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Financial numbers in USD